Ir para o conteúdo principal

Amneal Pharmaceuticals (NYSE: AMRX) — Perfil da empresa, notícias e dados financeiros

Logo de Amneal Pharmaceuticals
AMRX Amneal Pharmaceuticals
Amneal Pharmaceuticals  primary media
Perfil da empresa

Amneal Pharmaceuticals

Amneal Pharmaceuticals (NASDAQ:AMRX) is a dynamic company specializing in the development, manufacture, and distribution of generic and specialty pharmaceutical products. Primarily focusing on a wide range of therapeutic areas, Amneal aims to provide high-quality medications that improve patient outcomes while striving to make healthcare more accessible. With a robust pipeline of products aimed at addressing complex diseases, the company is dedicated to innovation and expanding its portfolio to meet diverse healthcare needs. Amneal's objectives revolve around leveraging its R&D capabilities to fuel growth, fostering strategic partnerships, and ensuring environmental sustainability in its operations, aiming to create value for both patients and stakeholders.

Resumo

Public USParticipação acionária
2002Ano de fundação
5113Funcionários
New Jersey, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Amneal Pharmaceuticals

  • Generic Pharmaceuticals: Producing high-quality generic pharmaceuticals across a variety of therapeutic areas.
  • Specialty Pharmaceuticals: Focused on developing unique treatments for complex diseases.
  • Biosimilars: Working on affordable alternatives to biologic drugs, emphasizing accessible healthcare.
  • Over-the-Counter Medications: Offering a range of over-the-counter products for various health needs.
  • Research and Development: Investing in innovative research to expand the pharmaceutical portfolio.
  • Partnerships and Collaborations: Engaging with other firms for development and distribution of pharmaceuticals.

equipe executiva do Amneal Pharmaceuticals

  • Chirag K. PatelCo-Founder, Co-CEO, President & Director
  • Chintu PatelCo-Founder, Co-CEO & Director
  • Anastasios G. KonidarisExecutive VP & CFO
  • Jason B. DalyExecutive VP, Chief Legal Officer & Corporate Secretary
  • Nikita ShahExecutive VP & Chief Human Resources Officer
  • Andrew S. BoyerExecutive VP and Chief Commercial Officer of Generics & Biosciences
  • Anthony DiMeoHead/VP of Investor Relations
  • Brandon SkopSenior Director of Corporate Communications
  • Gregory SgammatoSenior Vice President of Corporate Development
  • Pranav MehtaSenior VP of Strategic Sourcing & Supply Management

Principais indicadores financeiros

Resultados divulgados pela Amneal Pharmaceuticals , em USD.

Cap. de mercado
7,5 bi
Receita (TTM)
3,1 bi
P/L
43.8
LPA (diluído, TTM)
0.5
Dividend yield
—
Margem de lucro
5.1%
Receita e lucro anuais da Amneal Pharmaceuticals
Fim do ano fiscalReceitaResultado operacionalLucro líquido
3 bi423,1 mi72,1 mi
2,8 bi249,3 mi-116,9 mi
2,4 bi204,4 mi-84 mi
2,2 bi-94,9 mi-130 mi